This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Buy 5 Stocks With Upgraded Broker Ratings for Robust Returns
by Swayta Shah
Brokers have deeper insights into stocks and macroeconomic factors. So, one should follow broker rating upgrades to pick stocks like Skechers (SKX), Walmart (WMT), Haemonetics (HAE), AZZ Inc. (AZZ) and BOK Financial (BOKF).
Don't Overlook These Highly Ranked Medical Stocks as Markets Rise
by Shaun Pruitt
With earnings estimate revisions on the rise for these top medical stocks, they certainly shouldn't be overlooked given their blazing historical performances.
Best Momentum Stocks to Buy for June 6th
by Zacks Equity Research
HAE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 6, 2024.
New Strong Buy Stocks for June 6th
by Zacks Equity Research
HWM, LGND, MATX, SMFKY and HAE have been added to the Zacks Rank #1 (Strong Buy) List on June 6, 2024.
These 3 Companies Boast Bright Outlooks
by Derek Lewis
Listening to the Zacks Rank can consistently result in market-beating gains, as positive earnings estimate revisions provide the fuel needed for shares to move higher.
Best Momentum Stocks to Buy for June 4th
by Zacks Equity Research
CAMT, HAE and NMM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 4, 2023.
Why Haemonetics (HAE) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 Top GARP Picks for Your Portfolio Based on PEG Ratio
by Urmimala Biswas
Here are the five PEG-based GARP stocks that fit our screening criteria - DBX, HAE, PDD, BTG and ATGE.
Here's Why Haemonetics (HAE) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Highly Ranked Medical Stocks Added to the Zacks Strong Buy List
by Shaun Pruitt
Considering the stretched premiums many groundbreaking healthcare companies can command, these medical stocks are worthy of investors' interest given their attractive P/E valuations and the positive trend of earnings estimate revisions.
Best Momentum Stocks to Buy for May 28th
by Zacks Equity Research
MNSO, LSPD and HAE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 28, 2023.
3 Reasons Why Growth Investors Shouldn't Overlook Haemonetics (HAE)
by Zacks Equity Research
Haemonetics (HAE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
HAE or BSX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HAE vs. BSX: Which Stock Is the Better Value Option?
Wall Street Analysts Believe Haemonetics (HAE) Could Rally 26.58%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26.6% in Haemonetics (HAE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Haemonetics (HAE) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why You Should Buy Haemonetics (HAE) Stock Now
by Zacks Equity Research
Strong prospects of the Plasma franchise and favorable solvency bode well for Haemonetics (HAE).
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics' (HAE) Hospital & Plasma Segments, Innovation Aid
by Zacks Equity Research
Haemonetics' (HAE) hospital portfolio is evolving and helping to create new opportunities for growth and diversification.
Haemonetics (HAE) Stock Up 10.9% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Haemonetics (HAE) led by its strategic focus on establishing leading positions in high-growth markets to generate solid financial returns.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Haemonetics Corporation (HAE) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Haemonetics (HAE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Haemonetics (HAE) Q4 revenues were driven by an uptick in the Plasma and Hospital segments.
Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 2.27% and 5%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?